“Q1 represents an inflection point for the business and reflects the continued execution of the 2-year framework we have discussed over the past several quarters.” (CEO)
“MA funding rates improved approximately 15% year-over-year. Delegated functions expanded across 63% of membership in 2026, and contract alignment improved meaningfully across several of our largest relationships.” (CEO)
“The nearly flat MA medical cost trend that we are seeing in the quarter is not accidental. It is a result of deliberate clinical programs, improved utilization management workflows and enhanced payment integrity capabilities.” (CMO)
“Excluding the prior year items, underlying Q1 adjusted EBITDA was $8 million, reflecting the core operating performance of the business.” (CFO)
“The structural work is producing results. The contract restructuring, network concentration and operational redesign we have executed over the past 2 years are showing up in our economics.” (CEO)